Skip to content

Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients

To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients: A Double-Blind Randomized Controlled Trial - RNB

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025998
Enrollment
60
Registered
2020-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Raj Nirwan Bati capsule: 1. Mercury (Para) 2. Sulphur (Gandhak) 3. Gold (Sona) 4. Silver (Chandi) 5. Clamina Perpeta 6. Arsenic Trioxide (Hartal Bhasma) 7. Black pepper (Kaali Mirch) 8.

Sponsors

Uttar Pradesh University of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. RT-PCR confirmed SARS-CoV-2 infected symptomatic patients admitted to the COVID-19 hospital of UPUMS 2. Patients falling in mild, moderate and severe category of COVID-19 illness 3. Patients more than 18 years of age

Exclusion criteria

Exclusion criteria: 1. All critically ill patients of COVID-19 2. Patients not providing informed written consent for the study 3. Pregnant and lactating females 4. Patients of Chronic kidney disease (CKD) more than stage three 5. Asymptomatic cases 6. Study participants becoming critically ill during the course of intervention.

Design outcomes

Primary

MeasureTime frame
Micro-biologically becoming RT-PCR negative for SARS-CoV-2Timepoint: Micro-biologically RT-PCR results for SARS-CoV-2 shall be evaluated at baseline, day 6 and day 12

Secondary

MeasureTime frame
1. Persistence of symptoms beyond day 5 in mild cases and day 7 in moderate cases 2. Worsening of clinical features beyond day 5 except severe cases 3. Changes in bio-chemical parameters like LDH, CRP, SGPT, SGOT 4. Changes in haematological parameters 5. Radiological worsening. Timepoint: These parameters will be evaluated on day 1, day 6 and day 12 after start of intervention.

Countries

India

Contacts

Public ContactDr Raj Kumar

Uttar Pradesh University of Medical Sciences

nareshpalsingh@gmail.com09458641119

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026